Gan & Lee Pharmaceuticals Advances GLR2037 Tablet to Phase I Clinical Trial Stage with First Patient Dosed

Gan & Lee Pharmaceuticals Subsidiary Secures GMP Certification from Brazilian Health Authority

Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Shows Favorable Safety Profile With No Severe Hypoglycemic Events

Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Reduces Annual Injection Frequency by More Than 85% Compared to Once-Daily Insulins

Gan & Lee Pharmaceuticals - Gzr4 Injection Shows Superior Hba1c Reduction Versus Lantus and Tresiba After 26 Weeks

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin Gzr4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: Super-1 and Super-2

Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea

Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials

Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval

Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets

Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%

Gan & Lee Pharmaceuticals (603087.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Owners to Increase 78.96% to 95.23% YoY

Gan & Lee Pharmaceuticals (603087.SH): Insulin Glargine Injection and Its Pre-filled Pen Receive Drug Registration Approval in Ethiopia

Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4%

Sandoz Receives European Commission Approval for Ondibta Insulin Glargine

Gan & Lee Pharmaceuticals Dismisses CFO and Vice President

Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO

INDIA STOCKS-Indian equity benchmarks eye muted start on persistent foreign outflows

Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug

Once-Monthly Glp-1 Ra | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (Gradual-3) of the First Chinese Once-Monthly Glp-1 Ra for Weight Management